Paragard Litigation: Who Bears The Cost of Defective Contraception? -By Fransiscus Nanga Roka

As the multidistrict litigation (MDL) involving the U.S. manufacturers of Paragard—Teva Pharmaceuticals and CooperSurgical—continues this year in Georgia federal district court, it raises important issues regarding corporate responsibility, women’s reproductive health care, and the murky world of medical devices regulation. The case involves numerous scores of consolidated lawsuits that allege the metal IUD designed for copper usage possesses a uniquely frail ‘T’ frame which risks being torn apart during removal, leaving debris buried within the uterus.

Paragard was originally produced and marketed by Teva Pharmaceuticals, but is now manufactured by CooperSurgical, Inc. and the manufacturers of Paragard are facing lawsuits claiming defective product claims and failure to provide adequate warnings about associated risks of Paragard. The plaintiffs allege that the companies failed to uphold their obligations by not providing adequate warnings about the risk of the device’s arms breaking off, resulting in severe medical complications. It depends on whether the companies were negligent in their design, production, or communications related to healthcare providers and patients.

The lawsuits are about the alleged rupture of plastic arms left inside the uterine cavity thus not uncommon claim plaintiffs. These pieces can trigger a domino effect of invasive surgical procedures such as hysteroscopy or laparoscopy, some women being left with permanent fertility damage such is the severity and urgency for intervention. It comes as a nigh unprecedented example of ethical and medical risk assessment versus data integrity and conflict of interest vulnerability in the longterm safety profile of contraceptive devices, and who we can rightly determine pharmaceutical companies to be governing bodily sovereignty.

Backlash against this culture has mounted over the last couple of years as thousands of women have estimated that they suffered adverse events. This legal battle has really heated up since the consolidation into an MDL and the bellwether trials starting in 2023. Although early test cases such as the Pauline Rickards trial came back with a verdict for the manufacturer, that is not the end of it and more trials are set to challenge nuanced evidence regarding causation or federal labeling requirements.

Such a broad MDL is centralized in the federal district court for Georgia, chosen as generally recognized as appropriate venue with general subject matter over mass torts and belatedly maturing long term medical monitoring class action claims like these. The court is a place where the fight for science, regulation, and moral responsibility comes to pass.

Aside from individual plaintiffs’ suffering, the Paragard litigation highlights a troubling public health issue: The regulatory systems designed to help protect consumers against avoidable harms when using important medical devices—especially those that are completely utilized by women—appear to have fallen short. It raises the red flag over FDA surveillance, manufacturers’ warnings with an opaque transparency, and an imbalance of power between medical device manufacturers and the patients served.

Paragard litigation reveals severe systemic problems requiring concerted, multi-pronged solutions on the part of all market participants. It must be rigorous, analytical, and anchored in ethics to do no harm and rebuild trust.

Manufacturers have the primary responsibility to reinforce product design with uncompromising rigor. The regular breakage of the plastic arms of Paragard during removal indicates a basic flaw in material durability and engineering. We can no longer shrug off such events as isolated or “acceptable” risk. Patient safety must be prioritized in proactive redesign efforts above cost or convenience. The flip side of that is radical transparency: honest, straightforward communication about all possible risks—regardless of how inconvenient—has to be a starting point, not an afterthought. Such engagement is critical to restore the broken trust of patients and the profession itself.

Regulatory agencies such as the FDA need to augment post-market surveillance by establishing an effective real-time monitoring and vigilance mechanism. Troubling gaps in the current framework meant that reports of devices failing started to build up without firm action. There can be no compromise: warnings must be clear and easy to find in situation on the label/packaging that are impossible to miss. Furthermore, regulatory authorities have an obligation to require rapid reporting of adverse events and utilize aggressive measures ensure small issues do not snowball into a public health disaster. The story of the Paragard case is a cautionary tale about regulatory inertia that cannot drag on.

Healthcare providers are in a unique front-line position and deserve comprehensive, objective training** based on current evidence of device-related risks and removal practices. There is a need for more useable protocols for physicians and clinicians, not just in accessing safe device extraction but also in comprehensive informed consent. Patients should be fully informed of possible complications and other contraceptives before agreeing to have the Paragard inserted. This kind of extensive education, you imply, is what is necessary to reduce trauma and enable shared decision-making.

Judicial systems need to strike a balance between judicial case management efficiency on one hand and substantive justice on the other. †While bellwether trials are helpful litigation and case management tools, courts need to be careful not to trade in-depth consideration of scientific evidence and plaintiff testimony for expediency. Delays in justice is failure, but dilution of justice by taking procedural shortcuts is a betrayal. It is essential for courts to maintain strict standards that do not erase victims’ lived experiences or hide important technical information.

Third, patients want to be empowered through transparency and advocacy. Those who use contraception should have free access to accurate, clear information about Paragard’s risks and safer options so that they may make independent and informed decisions about their bodies and health. Advocacy groups, policy makers and healthcare systems must find ways to empower patients that go beyond rhetoric and have practical application.

The Paragard crisis is a wake-up call to reform Industry standards, regulatory scrutiny, medical training and patient rights. Only a holistic, collective response from all stakeholders based on safety, transparency, education, equity and autonomy can assure that this deeply damaging failure of women’s reproductive health care never happens again.

The Paragard MDL is more than a legal fight over product liability; it is an assessment of America’s many failings to adequately protect women’s health in reproductive technologies. This reveals the necessity of an intersectional approach in which ethical corporate conduct, regulation, medical accountability and patient rights decisively overlap. If these dimensions are not systematically addressed, there is a risk of continued preventable suffering and loss of public confidence in essential systems that provide care. Stakeholders must now face these challenges with unflinching resolve and collaborative strategic planning.

Fransiscus Nanga Roka

Faculty of Law University 17 August 1945 Surabaya and Managing Partner Law Firm Victorious Indonesia